VCNX Stock - Vaccinex, Inc.
Unlock GoAI Insights for VCNX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $601,000 | $570,000 | $100,000 | $900,000 | $50,000 |
| Gross Profit | $601,000 | $570,000 | $68,000 | $731,000 | $48,000 |
| Gross Margin | 100.0% | 100.0% | 68.0% | 81.2% | 96.0% |
| Operating Income | $-18,735,000 | $-22,885,000 | $-19,906,000 | $-22,490,000 | $-28,331,000 |
| Net Income | $-18,634,000 | $-20,251,000 | $-19,722,000 | $-22,380,000 | $-28,851,000 |
| Net Margin | -3100.5% | -3552.8% | -19722.0% | -2486.7% | -57702.0% |
| EPS | $-8.88 | $-43.68 | $-97.59 | $-163.80 | $-322.50 |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Visit WebsiteEarnings History & Surprises
VCNXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | — | — | — |
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q2 2025 | Apr 15, 2025 | — | $-1.61 | — | — |
Q1 2025 | Mar 31, 2025 | — | — | — | — |
Q4 2024 | Nov 14, 2024 | — | $-2.28 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-3.10 | — | — |
Q2 2024 | May 15, 2024 | — | $-2.94 | — | — |
Q2 2024 | Apr 2, 2024 | $-48.28 | $-39.40 | +18.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-54.77 | $-15.27 | +72.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-63.29 | $-25.20 | +60.2% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-63.36 | $-21.00 | +66.9% | ✓ BEAT |
Q2 2023 | Apr 3, 2023 | $-56.57 | $-23.10 | +59.2% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-56.70 | $-23.10 | +59.3% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-56.70 | $-27.30 | +51.9% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-56.70 | $-25.20 | +55.6% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-63.00 | $-31.50 | +50.0% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | — | $-35.70 | — | — |
Q3 2021 | Aug 16, 2021 | $-60.89 | $-44.10 | +27.6% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-81.89 | $-54.59 | +33.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about VCNX
What is VCNX's current stock price?
What is the analyst price target for VCNX?
What sector is Vaccinex, Inc. in?
What is VCNX's market cap?
Does VCNX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VCNX for comparison